|
1
|
Penha Mesquita A, Victor Oliveira Monteiro A, Luiz Araújo Bentes Leal A, Dos Santos Pessoa L, de Siqueira Amorim Júnior J, Rogério Souza Monteiro J, Andrade de Sousa A, Fernando Pereira Vasconcelos D, Carolina Alves de Oliveira A, Leão Pereira A, Rodolfo Pereira da Silva F. Gene variations related to the hepatocellular carcinoma: Results from a field synopsis and Bayesian revaluation. Gene 2023; 869:147392. [PMID: 36966980 DOI: 10.1016/j.gene.2023.147392] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 02/28/2023] [Accepted: 03/21/2023] [Indexed: 04/22/2023]
Abstract
Hepatocellular carcinoma (HCC) is considered as the second cause of cancer-related deaths worldwide. Genetic variations are associated with HCC risk, an issue that has been the subject of several meta-analyses. However, meta-analyses have an important limitation on the likelihood of false positive data. Henceforth, this study aimed to assess the level of noteworthiness in the meta-analyses by means of a Bayesian approach. A systematic search was performed for meta-analyses with associations between gene polymorphisms and HCC. The calculations for the False-Positive Rate Probability (FPRP) and the Bayesian False Discovery Probability (BFDP) were performed to assess the noteworthiness with a statistical power of 1.2 and 1.5 of Odds Ratio at a prior probability of 10-3 and 10-5. The quality of studies was evaluated by the Venice criteria. As additional analyses, the gene-gene and protein-protein networks were designed for these genes and products. As results, we found 33 meta-analytic studies on 45 polymorphisms occurring in 35 genes. A total of 1,280 values for FPRP and BFDP were obtained. Seventy-five for FPRP (5.86%) and 95 for BFDP (14.79%) were noteworthy. In conclusion, the polymorphisms in CCND1, CTLA4, EGF, IL6, IL12A, KIF1B, MDM2, MICA, miR-499, MTHFR, PNPLA3, STAT4, TM6SF2, and XPD genes were considered as noteworthy biomarkers for HCC risk.
Collapse
Affiliation(s)
- Abel Penha Mesquita
- Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil
| | | | | | - Larissa Dos Santos Pessoa
- Parnaiba Delta Federal University, Parnaiba, PI, Brazil; Laboratory of Histological Analysis and Preparation (LAPHIs), Parnaiba Delta Federal University, Parnaiba, PI, Brazil
| | | | | | - Aline Andrade de Sousa
- Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil
| | - Daniel Fernando Pereira Vasconcelos
- Parnaiba Delta Federal University, Parnaiba, PI, Brazil; Laboratory of Histological Analysis and Preparation (LAPHIs), Parnaiba Delta Federal University, Parnaiba, PI, Brazil
| | | | - Adenilson Leão Pereira
- Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil
| | | |
Collapse
|
|
3
|
Di Sarno R, Brigida A, Caprio GG, Ciardiello D, Dallio M, Sangineto M, Fagoonee S, Abenavoli L, Luzza F, Gravina AG, De Magistris L, Federico A, Loguercio C. Critical review on the use and abuse of alcohol. When the dose makes the difference. Minerva Med 2020; 111:344-353. [PMID: 32338485 DOI: 10.23736/s0026-4806.20.06584-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Nowadays harmful alcohol consumption represents one of the most important risk factors for the development of several type of chronic and acute diseases in the western countries, contributing to a great number of deaths. Focusing the attention on cancer development and progression, the scientific community has a large consensus in declaring the existence of a harmful association between alcohol consumption and liver, breast, upper aerodigestive tract (mouth, oropharynx, hypopharynx, and esophagus), pancreas and colon cancer appearance. However the precise biological links by which the alcohol could be responsible for cancer initiation and progression are not fully understood yet, even if the International Agency for Research on Cancer (IARC) indicated both ethanol and acetaldehyde as carcinogen for humans. The possible explanation of the effect exerted by ethanol and acetaldehyde could be related to direct genotoxicity, hormonal disturbance, triggering of oxidative stress and inflammation. In this review, we examine the relationship between alcohol dosage and associated diseases, with focus on alcohol-related cancers. Furthermore, to understand the potential molecular mechanisms of these diseases, the results of in vivo experiments on animal models were discussed.
Collapse
Affiliation(s)
- Rosa Di Sarno
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Annalisa Brigida
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Giuseppe G Caprio
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Davide Ciardiello
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Marcello Dallio
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy -
| | - Moris Sangineto
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Sharmila Fagoonee
- Institute of Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Turin, Italy
| | - Ludovico Abenavoli
- Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
| | - Francesco Luzza
- Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
| | - Antonietta G Gravina
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Laura De Magistris
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Alessandro Federico
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| | - Carmelina Loguercio
- Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
| |
Collapse
|
|
6
|
Gao J, Wang Z, Wang GJ, Zhang HX, Gao N, Wang J, Wang CE, Chang Z, Fang Y, Zhang YF, Zhou J, Jin H, Qiao HL. Higher CYP2E1 Activity Correlates with Hepatocarcinogenesis Induced by Diethylnitrosamine. J Pharmacol Exp Ther 2018; 365:398-407. [PMID: 29467309 DOI: 10.1124/jpet.117.245555] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Accepted: 01/08/2018] [Indexed: 03/08/2025] Open
Abstract
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer and the third most frequent cause of cancer death worldwide. Diethylnitrosamine (DEN) is one of the recognized risk factors for hepatocarcinogenesis likely due to CYP2E1-mediated metabolic activation. However, CYP2E1-mediated DEN metabolic activity in non-neoplastic liver tissue from HCC patients has not been determined; the role of CYP2E1 activity, in particular CYP2E1 constitutive activity and CYP2E1 inhibited activity, with respect to the hepatocarcinogenesis induced by DEN is not yet clear. Herein, we determined CYP2E1-mediated DEN metabolic activity in non-neoplastic liver tissue from HCC patients and found that CYP2E1-mediated DEN metabolic activity was significantly elevated with a 43.3% positive rate, and clinicopathologic parameters did not affect the activity. Then, using a Sprague-Dawley rat liver tumor model induced by DEN, the relationship between CYP2E1 constitutive/inhibited activity and hepatocarcinogenesis was explored. The results showed that the CYP2E1 constitutive activity was strongly correlated with tumor incidence and severity of liver tumorigenesis (nodule numbers and size), whereas inhibition of CYP2E1 activity decreased hepatocyte proliferation, liver injury, and liver carcinogenesis in the presence of DEN. In conclusion, the higher CYP2E1 activity would lead to an increased incidence of HCC as a result of CYP2E1-mediated DEN activation. Therefore, higher CYP2E1 activity might be a risk factor for HCC induced by DEN.
Collapse
Affiliation(s)
- Jie Gao
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Zhao Wang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Gao-Ju Wang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Hong-Xin Zhang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Na Gao
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Jie Wang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Cai-E Wang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Zhao Chang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Yan Fang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Yun-Fei Zhang
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Jun Zhou
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Han Jin
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| | - Hai-Ling Qiao
- Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, China (J.G., Z.W., G.-J.W., H.-X.Z., N.G., J.W., C.-E.W., Z.C., Y.F., Y.-F.Z., J.Z., H.J., H.-L.Q.); First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (H.-X.Z.); Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (Y.-F.Z.); and Affiliated Provincial People's Hospital of Zhengzhou University, Zhengzhou, Henan, China (J.Z.)
| |
Collapse
|
|
9
|
Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, McKillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. Exp Mol Pathol 2015; 99:596-610. [PMID: 26342547 DOI: 10.1016/j.yexmp.2015.09.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 09/01/2015] [Indexed: 02/05/2023]
Abstract
The present review spans a broad spectrum of topics dealing with alcoholic liver disease (ALD), including clinical research, translational research, pathogenesis and therapies. A special accent is placed on alcohol misuse, as alcohol is a legally commercialized and taxable product. Drinking alcohol, particularly from a young age, is a major health problem. Alcoholism is known to contribute to morbidity and mortality. A systematic literature search was performed in order to obtain updated data (2008-2015). The review is focused on genetic polymorphisms of alcohol metabolizing enzymes and the role of cytochrome p450 2E1 and iron in ALD. Alcohol-mediated hepatocarcinogenesis is also discussed in the presence or absence of co-morbidities such as viral hepatitis C as well as therapeutic the role of innate immunity in ALD-HCV. Moreover, emphasis was placed on alcohol and drug interactions, as well as liver transplantation for end-stage ALD. Finally, the time came to eradicate alcohol-induced liver and intestinal damage by using betaine.
Collapse
Affiliation(s)
- Manuela G Neuman
- In Vitro Drug Safety and Biotechnology, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
| | - Stephen Malnick
- Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel
| | - Yaakov Maor
- Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel
| | - Radu M Nanau
- In Vitro Drug Safety and Biotechnology, Toronto, Ontario, Canada
| | - Ehud Melzer
- Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel
| | | | - Helmut K Seitz
- University of Heidelberg, Heidelberg, Germany; Department of Medicine, Gastroenterology and Hepatology, Centre for Alcohol Research, Salem Medical Centre, Heidelberg, Germany
| | - Sebastian Mueller
- University of Heidelberg, Heidelberg, Germany; Department of Medicine, Gastroenterology and Hepatology, Centre for Alcohol Research, Salem Medical Centre, Heidelberg, Germany
| | - Haim Mell
- Israel Antidrug and Alcohol Authority, Jerusalem, Israel
| | - Didier Samuel
- Liver Transplant Unit, Research Inserm-Paris XI Unit 785, Centre Hepatobiliaire, Hopital Paul Brousse, Villejuif, Paris, France
| | - Lawrence B Cohen
- Division of Gastroenterology, Sunnybrook Health Sciences Centre and Department of Internal Medicine, University of Toronto, Toronto, Canada
| | - Kusum K Kharbanda
- Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Natalia A Osna
- Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Murali Ganesan
- Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Kyle J Thompson
- Department of Surgery, Carolinas Medical Center, Charlotte, NC 28203, USA
| | - Iain H McKillop
- Department of Surgery, Carolinas Medical Center, Charlotte, NC 28203, USA
| | - Abraham Bautista
- Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA
| | - Ramon Bataller
- Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | |
Collapse
|